Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04064229 · ClinicalTrials.gov registry record · NA
ivWatch Sensor: Device Validation for Infiltrated Tissues
A NA study of Infiltration of Peripheral IV Therapy, sponsored by ivWatch.
- Completed
- Registry status
- NA
- Development phase
- 99
- Enrollment target
- 1
- Study location
NCT04064229: Completed NA study of Infiltration of Peripheral IV Therapy, sponsored by ivWatch.
NCT04064229 is a NA study of Infiltration of Peripheral IV Therapy that has completed, run by ivWatch. The registered enrollment target is 99 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04064229, a NA study of Infiltration of Peripheral IV Therapy, has completed, sponsored by ivWatch.
- COMPLETED
- Registry status
- NA
- Development phase
- 99 participants
- Enrollment target
- 1
- Study location
Study Summary
A single arm trial consisting of 98 adult volunteers to assess the safety and efficacy of ivWatch sensors when observing infiltrated tissues at common sites for peripheral IV therapy.
Primary Outcome
The ratio of the number of infiltrated IV sites where the ivWatch Model 400 device issued a red notification to the total number of infiltrated IV sites in the study. All infiltrations were limited to 10 mL of isotonic saline solution.
Conditions Studied
Interventions
- DEVICE ivWatch Model 400 with SmartTouch Sensor
- DEVICE ivWatch Model 400 with Fiber Optic Sensor
Study Locations (1)
Virginia
- ivWatch, LLC - Williamsburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2019-04-03 |
| Est. Completion | 2019-04-09 |
| Phase | NA |
What the finished NCT04064229 record still lists
NCT04064229 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Infiltration of Peripheral IV Therapy appearing as the primary indexed condition, and to 2 interventions - of which ivWatch Model 400 with SmartTouch Sensor is the first listed.
NCT04064229 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT04064229 about?
NCT04064229 is a clinical study titled "ivWatch Sensor: Device Validation for Infiltrated Tissues". A single arm trial consisting of 98 adult volunteers to assess the safety and efficacy of ivWatch sensors when observing infiltrated tissues at common sites for peripheral IV therapy.
What is the current status of trial NCT04064229?
This trial is currently completed. It is a NA study. The enrollment target is 99 participants. The study started on 2019-04-03. Estimated completion is 2019-04-09.
What conditions does trial NCT04064229 study?
This clinical trial studies the following conditions: Infiltration of Peripheral IV Therapy.
What interventions are being tested in trial NCT04064229?
The interventions under investigation include: ivWatch Model 400 with SmartTouch Sensor (DEVICE), ivWatch Model 400 with Fiber Optic Sensor (DEVICE).
Who is sponsoring clinical trial NCT04064229?
This trial is sponsored by ivWatch, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04064229 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infiltration of Peripheral IV Therapy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04064229's enrollment target sits among peer trials
99 920th of 2000 higher than 1,079 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI